Peter R. Galle, MD, PhD, Mainz University Medical Center

Articles

Evolving HCC Treatment Landscape: Combination Therapy

October 30th 2020

Developing Trial Regimens for Chinese Populations

October 30th 2020

High AFP as Deciding Factor for Treatment

October 30th 2020

Immunotherapy Monotherapy in Later-Line Setting

October 30th 2020

Second-Line Options After IMbrave150 Regimen

October 30th 2020

Promising Ongoing Frontline Trials

October 30th 2020

Importance of Endoscopy in Newly Diagnosed HCC

October 30th 2020

NCCN Guidelines: Nivolumab in Frontline Setting

October 30th 2020

Choosing a Frontline Therapy

October 30th 2020

Optimal HCC Frontline Treatments

October 30th 2020

The TACE Approach for Intermediate-Stage Disease

October 30th 2020

The BCLC Staging System

October 30th 2020

Screening Vs Diagnosis: Assessing Liver Function

October 30th 2020

The Complexity of HCC Multidisciplinary Management

October 30th 2020

Emerging Therapies for HCC Management

June 29th 2020

Metastatic HCC Unmet Needs

June 29th 2020

I/O Second-Line Treatment

June 29th 2020

REACH and REACH2 Trial Overview

June 29th 2020

Second-Line Therapy: Monoclonal Antibody

June 29th 2020

Second-Line Sequencing After IMbrave150 Regimen

June 29th 2020